<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998828</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-354-0101</org_study_id>
    <secondary_id>2013-004105-11</secondary_id>
    <nct_id>NCT01998828</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia</brief_title>
  <official_title>A Phase 2, Open-label, Randomized Study to Evaluate the Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sierra Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sierra Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label study is to determine the safety and efficacy of momelotinib in participants&#xD;
      with either polycythemia vera (PV) or essential thrombocythemia (ET) who have not yet&#xD;
      received treatment with a Janus kinase (JAK) inhibitor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">February 19, 2014</start_date>
  <completion_date type="Actual">May 7, 2015</completion_date>
  <primary_completion_date type="Actual">March 17, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>For the PV Cohort, overall response rate (ORR) is defined as the proportion of participants with all of the following at some point during the treatment period:&#xD;
Hematocrit &lt; 45% in the absence of phlebotomy that lasts at least 4 weeks&#xD;
White blood cell (WBC) count &lt; 10 x 10^9/L that lasts at least 4 weeks&#xD;
Platelet count ≤ 400 x 10^9/L that lasts at least 4 weeks&#xD;
Resolution of palpable splenomegaly that lasts at least 4 weeks&#xD;
For the ET Cohort, overall response rate is defined as the proportion of participants with all of the following at some point during the treatment period:&#xD;
WBC count &lt; 10 x 10^9/L that lasts at least 4 weeks&#xD;
Platelet count ≤ 400 x 10^9/L that lasts at least 4 weeks&#xD;
Resolution of palpable splenomegaly that lasts at least 4 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirmed overall response rate</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Confirmed overall response rate is defined as the proportion of participants who meet all the criteria listed for the primary endpoints of PV or ET, sustained for at least 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with hematocrit &lt; 45% in the absence of phlebotomy that lasts at least 4 weeks</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with WBC &lt; 10 x 10^9/L that lasts at least 4 weeks</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with platelet count ≤ 400 x 10^9/L that lasts at least 4 weeks</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with resolution of palpable splenomegaly that lasts at least 4 weeks</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with ≥ 10 point decrease in modified Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPNSAF TSS) compared to baseline that lasts at least 12 weeks</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Polycythemia Vera</condition>
  <condition>Essential Thrombocythemia</condition>
  <arm_group>
    <arm_group_label>Momelotinib 100 mg PV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with polycythemia vera will receive 100 mg of momelotinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Momelotinib 200 mg PV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with polycythemia vera will receive 200 mg of momelotinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Momelotinib 100 mg ET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with essential thrombocythemia will receive 100 mg of momelotinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Momelotinib 200 mg ET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with essential thrombocythemia will receive 200 mg of momelotinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Momelotinib</intervention_name>
    <description>Momelotinib tablet administered orally once daily</description>
    <arm_group_label>Momelotinib 100 mg ET</arm_group_label>
    <arm_group_label>Momelotinib 100 mg PV</arm_group_label>
    <arm_group_label>Momelotinib 200 mg ET</arm_group_label>
    <arm_group_label>Momelotinib 200 mg PV</arm_group_label>
    <other_name>GS-0387</other_name>
    <other_name>CYT387</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of either PV or ET as defined by the 2008 World Health Organization (WHO)&#xD;
             Diagnostic Criteria&#xD;
&#xD;
          -  Requires treatment for PV or ET, in the opinion of the study investigator&#xD;
&#xD;
          -  Intolerant of, resistant to, or refuses current or available treatment for PV or ET&#xD;
&#xD;
          -  Direct bilirubin ≤ 2.0 x upper limit of the normal range (ULN)&#xD;
&#xD;
          -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN&#xD;
&#xD;
          -  Calculated creatinine clearance (CrCl) of ≥ 45 mL/min&#xD;
&#xD;
          -  Life expectancy &gt; 24 weeks&#xD;
&#xD;
          -  Male subjects and female subjects of childbearing potential who engage in heterosexual&#xD;
             intercourse must agree to use protocol specified method(s) of contraception&#xD;
&#xD;
          -  Females who are nursing must agree to discontinue nursing before the first dose of&#xD;
             study drug&#xD;
&#xD;
          -  Able to comprehend and willing to sign informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior splenectomy&#xD;
&#xD;
          -  Uncontrolled intercurrent illness, per protocol&#xD;
&#xD;
          -  Known positive status for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Chronic active or acute viral hepatitis A, B, or C infection, or hepatitis B or C&#xD;
             carrier&#xD;
&#xD;
          -  Myeloproliferative neoplasm-directed therapy, other than aspirin, hydroxyurea,&#xD;
             anagrelide, and/or phlebotomy, within 21 days prior to the first dose of study drug&#xD;
&#xD;
          -  Anagrelide within 7 days prior to the first dose of study drug&#xD;
&#xD;
          -  Presence of peripheral neuropathy ≥ Grade 2&#xD;
&#xD;
          -  Unwilling or unable to take oral medication&#xD;
&#xD;
          -  Prior use of a JAK1 or JAK2 inhibitor&#xD;
&#xD;
          -  Use of strong CYP3A4 inducers within 1 week prior to the first dose of study drug&#xD;
&#xD;
          -  QTc interval &gt; 450 msec, unless attributed to bundle branch block&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Lee, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 25, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2013</study_first_posted>
  <disposition_first_submitted>April 26, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 26, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 25, 2016</disposition_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polycythemia</keyword>
  <keyword>Polycythemia Vera</keyword>
  <keyword>Essential Thrombocythemia</keyword>
  <keyword>Thrombocytosis</keyword>
  <keyword>Myeloproliferative Disorders</keyword>
  <keyword>Bone Marrow Diseases</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Blood Coagulation Disorders</keyword>
  <keyword>Blood Platelet Disorders</keyword>
  <keyword>Hemorrhagic Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

